Chardan Capital Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $325.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price lifted by stock analysts at Chardan Capital from $300.00 to $325.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s price objective indicates a potential upside of 25.29% from the stock’s previous close.

ALNY has been the subject of a number of other reports. Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Bank of America increased their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Citigroup boosted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a report on Friday, March 21st. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $319.17.

Alnylam Pharmaceuticals Trading Up 1.7 %

Shares of Alnylam Pharmaceuticals stock opened at $259.39 on Friday. Alnylam Pharmaceuticals has a 12-month low of $144.73 and a 12-month high of $304.39. The firm’s 50 day simple moving average is $248.21 and its two-hundred day simple moving average is $254.99. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $33.74 billion, a price-to-earnings ratio of -119.53 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share. Analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,392 shares of company stock valued at $1,875,627 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $28,000. Whipplewood Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 71 shares during the last quarter. Bessemer Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 69 shares during the period. Finally, R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $33,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.